stockrow
Saturday 7 November 2026
Export NVCT’s income statement to Excel — free account
Nuvectis Pharma, Inc.
NVCT Healthcare Biotechnology
- EPS
- −131.9%
- Free cash flow
- −34.6%
Quarter to September 2026, against a year earlier
20.81
3.05
+17.17%
Follow NVCT
Alert me
Nuvectis Pharma, Inc. (NVCT) P/E ratio
Nuvectis Pharma, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KURA Kura Oncology, Inc. compare | n/m |
| OLMA Olema Pharmaceuticals, Inc. compare | n/m |
| AVBP ArriVent BioPharma, Inc. compare | n/m |
| NVCT Nuvectis Pharma, Inc. | n/m |
| ACRS Aclaris Therapeutics, Inc. compare | n/m |
| IMMX Immix Biopharma, Inc. compare | n/m |
| APMD Apnimed, Inc. compare | 0.8× |
| ANL Adlai Nortye Ltd. Sponsored ADR compare | — |
| OBX Obsidian Therapeutics, Inc compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)